

Klas G Wiman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800205/publications.pdf>

Version: 2024-02-01

115
papers

10,570
citations

31976

53
h-index

32842

100
g-index

124
all docs

124
docs citations

124
times ranked

10209
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolutionary history of the p53 family DNA-binding domain: insights from an <i>Alvinella pompejana</i> homolog. <i>Cell Death and Disease</i> , 2022, 13, 214.	6.3	10
2	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021, 28, 1477-1492.	11.2	26
3	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. <i>Cell Death and Disease</i> , 2021, 12, 709.	6.3	11
4	A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. <i>EMBO Molecular Medicine</i> , 2021, 13, e10852.	6.9	28
5	Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. <i>Cell Death Discovery</i> , 2020, 6, 42.	4.7	55
6	Functional characterization of novel germline TP53 variants in Swedish families. <i>Clinical Genetics</i> , 2019, 96, 216-225.	2.0	7
7	p53 as a hub in cellular redox regulation and therapeutic target in cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 330-341.	3.3	71
8	Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246. <i>Journal of Clinical Oncology</i> , 2019, 37, e14712-e14712.	1.6	0
9	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. <i>Cell Death and Disease</i> , 2018, 9, 439.	6.3	182
10	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2670-2681.	1.4	77
11	Targeting mutant p53 for efficient cancer therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 89-102.	28.4	655
12	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. <i>Translational Oncology</i> , 2018, 11, 1343-1349.	3.7	25
13	Role of Thiol Reactivity for Targeting Mutant p53. <i>Cell Chemical Biology</i> , 2018, 25, 1219-1230.e3.	5.2	20
14	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. <i>Scientific Reports</i> , 2018, 8, 12671.	3.3	53
15	Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. <i>Cell Death and Disease</i> , 2017, 8, e2848-e2848.	6.3	76
16	Inhibiting the system x ^c /glutathione axis selectively targets cancers with mutant-p53 accumulation. <i>Nature Communications</i> , 2017, 8, 14844.	12.8	229
17	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. <i>Frontiers in Oncology</i> , 2017, 7, 323.	2.8	22
18	Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis. <i>Oncotarget</i> , 2016, 7, 1895-1911.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 21.	2.8	99
20	Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 27.	3.0	51
21	cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. <i>Cell Cycle</i> , 2016, 15, 1267-1275.	2.6	13
22	Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells. , 2016, , .		0
23	APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. <i>Cell Death and Disease</i> , 2015, 6, e1794-e1794.	6.3	151
24	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. <i>Gut</i> , 2015, 64, 1506-1516.	12.1	84
25	Abstract 110: The role of the p53 target Wig-1 in senescence and cancer. , 2015, , .		0
26	Abstract 1639: Strong synergy with APR-246 and DNA-damaging drugs in primary ovarian cancer cells. , 2015, , .		0
27	Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. , 2015, , .		1
28	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in <i>p53</i> . <i>Genes and Development</i> , 2014, 28, 58-70.	5.9	156
29	Mutant p53 reactivation by small molecules makes its way to the clinic. <i>FEBS Letters</i> , 2014, 588, 2622-2627.	2.8	154
30	Abstract 1849: High nuclear expression of the p53 target Wig-1 is associated with poor prognosis in cervical carcinoma. , 2014, , .		1
31	Abstract 1801: APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin. , 2014, , .		0
32	Expression of the p53 Target Wig-1 Is Associated with HPV Status and Patient Survival in Cervical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e111125.	2.5	2
33	Targeting Mutant p53 for Improved Cancer Therapy. , 2013, , 257-273.		0
34	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. <i>Cell Death and Disease</i> , 2013, 4, e881-e881.	6.3	142
35	APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2157-2162.	7.1	37
36	Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1 ^{MET} . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2152-2156.	7.1	69

#	ARTICLE	IF	CITATIONS
37	Abstract 3448: Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients.. , 2013, , .		0
38	p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. <i>Cell Cycle</i> , 2012, 11, 4563-4569.	2.6	19
39	Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3633-3639.	1.6	346
40	Regulation of tumor suppressor p53 at the RNA level. <i>Journal of Molecular Medicine</i> , 2010, 88, 645-652.	3.9	61
41	Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. <i>Oncogene</i> , 2010, 29, 1329-1338.	5.9	95
42	PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73. <i>Oncogene</i> , 2010, 29, 6442-6451.	5.9	54
43	Extract from Asteraceae <i>Brachylaena ramiflora</i> induces apoptosis preferentially in mutant p53-expressing human tumor cells. <i>Carcinogenesis</i> , 2010, 31, 1045-1053.	2.8	14
44	Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. <i>Carcinogenesis</i> , 2010, 31, 1475-1482.	2.8	55
45	WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies. <i>PLoS Biology</i> , 2010, 8, e1000521.	5.6	116
46	The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 85-89.	2.1	225
47	Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer. <i>Blood</i> , 2010, 116, 1806-1806.	1.4	1
48	The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15756-15761.	7.1	80
49	Mutant p53 rescue and modulation of p53 redox state. <i>Cell Cycle</i> , 2009, 8, 2509-2517.	2.6	43
50	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. <i>Cancer Cell</i> , 2009, 15, 376-388.	16.8	508
51	Regulation of p53R2 and its role as potential target for cancer therapy. <i>Cancer Letters</i> , 2009, 276, 1-7.	7.2	40
52	Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. <i>Molecular Cell</i> , 2009, 33, 462-471.	9.7	242
53	PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. <i>Molecular Cancer</i> , 2009, 8, 23.	19.2	6
54	Low p14ARF expression inde novoacute myeloid leukemia with normal karyotype is associated with poor survival. <i>Leukemia and Lymphoma</i> , 2009, 50, 1512-1518.	1.3	4

#	ARTICLE	IF	CITATIONS
55	30 years and a long way into p53 research. <i>Lancet Oncology</i> , The, 2009, 10, 913-919.	10.7	63
56	The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA Helicase A via RNA. <i>FEBS Letters</i> , 2008, 582, 2173-2177.	2.8	21
57	Mutant p53 targeting by the low molecular weight compound STIMA-1. <i>Molecular Oncology</i> , 2008, 2, 70-80.	4.6	91
58	PRIMA-1met radiosensitizes prostate cancer cells independent of their MTP53-status. <i>Radiotherapy and Oncology</i> , 2008, 86, 407-411.	0.6	36
59	In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. <i>Carcinogenesis</i> , 2008, 29, 1428-1434.	2.8	28
60	PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. <i>Cellular Oncology</i> , 2008, 30, 411-8.	1.9	40
61	p53 targets identified by protein expression profiling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5401-5406.	7.1	95
62	Restoration of Wild-type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy. <i>Advances in Cancer Research</i> , 2007, 97, 321-338.	5.0	29
63	Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm. <i>Cancer Cell</i> , 2007, 12, 303-312.	16.8	316
64	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		1
65	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		0
66	The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs. <i>FEBS Letters</i> , 2006, 580, 4401-4408.	2.8	17
67	hTERT antagonizes p53-induced apoptosis independently of telomerase activity. <i>Oncogene</i> , 2005, 24, 1320-1327.	5.9	150
68	PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. <i>Oncogene</i> , 2005, 24, 3484-3491.	5.9	216
69	Wig-1, a p53-Induced Zinc Finger Protein that Binds Double Stranded RNA. , 2005, , 76-79.		0
70	Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. <i>Journal of Biological Chemistry</i> , 2005, 280, 30384-30391.	3.4	207
71	The p53-induced Wig-1 zinc finger protein is highly conserved from fish to man. <i>International Journal of Oncology</i> , 2004, 24, 1559-64.	3.3	9
72	Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. <i>Oncogene</i> , 2003, 22, 4993-5005.	5.9	78

#	ARTICLE	IF	CITATIONS
73	Novel cancer therapy by reactivation of the p53 apoptosis pathway. <i>Annals of Medicine</i> , 2003, 35, 458-465.	3.8	52
74	Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13303-13307.	7.1	145
75	The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. <i>Nucleic Acids Research</i> , 2002, 30, 1991-1996.	14.5	48
76	Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. <i>Carcinogenesis</i> , 2002, 23, 2011-2018.	2.8	152
77	Identification of functional p53-binding motifs in the mouse wig-1 promoter. <i>FEBS Letters</i> , 2002, 524, 69-72.	2.8	14
78	A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. <i>Cancer Letters</i> , 2002, 180, 211-221.	7.2	15
79	Role of genetic and epigenetic changes in Burkitt lymphoma. <i>Seminars in Cancer Biology</i> , 2002, 12, 381-387.	9.6	98
80	Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. <i>Oncogene</i> , 2002, 21, 2119-2129.	5.9	173
81	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. <i>Nature Medicine</i> , 2002, 8, 282-288.	30.7	981
82	A novel high-through-put assay for screening of pro-apoptotic drugs. <i>Investigational New Drugs</i> , 2002, 20, 253-259.	2.6	103
83	Functional Rescue of Mutant p53 as a Strategy to Combat Cancer. , 2002, , 397-415.		2
84	p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. <i>Oncogene</i> , 2001, 20, 2171-2177.	5.9	88
85	Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. <i>Oncogene</i> , 2001, 20, 5466-5474.	5.9	60
86	p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas. <i>Brain Pathology</i> , 2001, 11, 159-168.	4.1	197
87	Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. <i>Oncogene</i> , 2000, 19, 5123-5133.	5.9	235
88	Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus. <i>Experimental Cell Research</i> , 2000, 256, 400-410.	2.6	79
89	p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. <i>Gene</i> , 2000, 246, 247-254.	2.2	18
90	p53 as a target for improved cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 347-353.	1.0	3

#	ARTICLE	IF	CITATIONS
91	p53-Induced Apoptosis as a Safeguard against Cancer. <i>Biochemical and Biophysical Research Communications</i> , 1999, 265, 1-6.	2.1	80
92	Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain. <i>Molecular and Cellular Biology</i> , 1999, 19, 3395-3402.	2.3	145
93	Reactivation of mutant p53: a new strategy for cancer therapy. <i>Seminars in Cancer Biology</i> , 1998, 8, 369-378.	9.6	64
94	Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?. <i>Oncogene</i> , 1998, 17, 2333-2337.	5.9	25
95	New p53-based anti-cancer therapeutic strategies. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1998, 15, 222-228.	1.1	16
96	p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma. <i>Blood</i> , 1998, 91, 1680-1687.	1.4	90
97	p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma. <i>Blood</i> , 1998, 91, 1680-1687.	1.4	7
98	p53: Emergency Brake and Target for Cancer Therapy. <i>Experimental Cell Research</i> , 1997, 237, 14-18.	2.6	28
99	Wig-1, a new p53-induced gene encoding a zinc finger protein. <i>Oncogene</i> , 1997, 15, 2699-2704.	5.9	66
100	Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. <i>Nature Medicine</i> , 1997, 3, 632-638.	30.7	348
101	An old acquaintance resurfaces in human mesothelioma. <i>Nature Medicine</i> , 1997, 3, 839-840.	30.7	23
102	Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. , 1996, 66, 322-325.		62
103	Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma. , 1996, 67, 106-112.		18
104	The single-stranded DNA end binding site of p53 coincides with the C- terminal regulatory region. <i>Nucleic Acids Research</i> , 1996, 24, 3560-3567.	14.5	61
105	RB-reconstituted human retinoblastoma cells form RB-positive intraocular and intracerebral but not subcutaneous tumors in scid mice. <i>International Journal of Cancer</i> , 1995, 61, 683-691.	5.1	4
106	p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. <i>Nucleic Acids Research</i> , 1995, 23, 362-369.	14.5	163
107	Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene. <i>Carcinogenesis</i> , 1995, 16, 2515-2521.	2.8	37
108	p53: A Cell Cycle Regulator Activated by DNA Damage. <i>Advances in Cancer Research</i> , 1995, 66, 143-180.	5.0	107

#	ARTICLE	IF	CITATIONS
109	What is the restriction point?. <i>Current Opinion in Cell Biology</i> , 1995, 7, 835-842.	5.4	320
110	A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. <i>Gene</i> , 1995, 162, 231-234.	2.2	2
111	Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. <i>International Journal of Cancer</i> , 1994, 58, 474-479.	5.1	21
112	Position-dependent nuclear accumulation of the retinoblastoma (RB) protein during in vitro myogenesis. <i>Journal of Cellular Physiology</i> , 1993, 155, 313-322.	4.1	10
113	The retinoblastoma gene: role in cell cycle control and cell differentiation. <i>FASEB Journal</i> , 1993, 7, 841-845.	0.5	129
114	Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. <i>Nature</i> , 1984, 307, 334-340.	27.8	272
115	Cancer Therapy by Reactivation of the p53 Apoptosis Pathway. , 0, , 891-912.		0